William Blair reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA - Free Report) in a research note issued to investors on Monday morning,RTT News reports. The firm currently has a $14.00 price objective on the stock.
A number of other equities analysts also recently issued reports on the stock. Wedbush reiterated a "neutral" rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, November 7th. Royal Bank of Canada reiterated an "outperform" rating and set a $54.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Barclays dropped their price objective on shares of Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating on the stock in a research note on Friday, November 8th. The Goldman Sachs Group decreased their target price on shares of Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Intellia Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $53.88.
Get Our Latest Research Report on NTLA
Intellia Therapeutics Price Performance
NTLA stock traded up $0.20 during mid-day trading on Monday, reaching $14.17. The company had a trading volume of 5,612,627 shares, compared to its average volume of 1,699,631. The company has a market capitalization of $1.44 billion, a PE ratio of -2.58 and a beta of 1.81. The firm has a 50 day moving average of $18.64 and a 200 day moving average of $22.04. Intellia Therapeutics has a 12 month low of $13.54 and a 12 month high of $34.87.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same quarter in the prior year, the business posted ($1.38) earnings per share. Intellia Therapeutics's revenue for the quarter was down 24.1% on a year-over-year basis. Analysts anticipate that Intellia Therapeutics will post -5.13 EPS for the current year.
Insider Buying and Selling
In related news, CAO Michael P. Dube sold 2,012 shares of the firm's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company's stock, valued at $893,698.12. This trade represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.20% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its holdings in shares of Intellia Therapeutics by 2.2% during the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company's stock worth $48,164,000 after purchasing an additional 49,367 shares during the last quarter. Barclays PLC grew its position in Intellia Therapeutics by 17.7% during the third quarter. Barclays PLC now owns 292,795 shares of the company's stock valued at $6,017,000 after buying an additional 44,022 shares during the period. Two Sigma Advisers LP grew its position in Intellia Therapeutics by 33.5% during the third quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company's stock valued at $21,118,000 after buying an additional 257,700 shares during the period. Sphera Funds Management LTD. grew its position in Intellia Therapeutics by 108.8% during the third quarter. Sphera Funds Management LTD. now owns 291,080 shares of the company's stock valued at $5,982,000 after buying an additional 151,661 shares during the period. Finally, State Street Corp grew its position in Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock valued at $105,700,000 after buying an additional 780,754 shares during the period. Hedge funds and other institutional investors own 88.77% of the company's stock.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Further Reading
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
